title: Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience.
abstract: OBJECTIVE
  This study reports the first evaluation of therapeutic response in Romanian patients with Gaucher disease type I, after therapy with Cerezyme recently became available in our country.
  
  
  METHODS
  24 patients (11-50 years) received Cerezyme 20-60 U/kg every two weeks for at least 18 months. Haemoglobin, platelet count, volume of the liver and spleen, plasma chitotriosidase and the severity score were assessed every 6 months; skeletal radiography and osteodensitometry were also monitored.
  
  
  RESULTS
  Eleven patients were splenectomized before start of therapy. Eight patients had anaemia (mean haemoglobin 9.4 g/dl) and 14 patients, of whom 13 were without splenectomy, had thrombocytopenia (mean 65,692/mm3). Haemoglobin values normalized after 6 months and the platelet count increased to 147,818/mm3 after 18 months of treatment. Splenomegaly improved (mean 13.8x to 5.6x normal), hepatomegaly improved (mean 1.4x to 1.06x normal), the severity score decreased (mean 15.9 to 8.4), plasma chitotriosidase levels showed a reduction from 40,956 to 11,266 nmol/h per ml plasma. Bone disease improved clinically in all patients; bone radiography and osteodensitometry showed no further disease progress. We observed a mean weight gain of 4.3 kg, an improvement in quality of life, and the absence of therapeutic adverse events.
  
  
  CONCLUSIONS
  Enzyme replacement therapy administered for 18 months in Romanian patients with Gaucher disease type I led to a marked improvement in haematological parameters and hepato- and splenomegaly. In the majority of patients we observed no further progress of bone disease; for an improvement in skeletal disease, a longer treatment period is required.
authors: 1st Pediatric Clinic, Iuliu Hatieganu University of Medicine and Pharmacy Cluj, 68 Motilor str., CP 494, of Cluj 1, 400370, Cluj, Romania. pgrigorescu@yahoo.co.uk
authors: P
authors: P
authors: Grigorescu Sido
authors: C
authors: C
authors: Drugan
authors: V
authors: V
authors: Cret
authors: C
authors: C
authors: Al-Kzouz
authors: C
authors: C
authors: Denes
authors: C
authors: C
authors: Coldea
authors: A
authors: A
authors: Zimmermann
mesh_terms: D000293:Adolescent; D000328:Adult; D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D001847:Bone Diseases / Q000188:drug therapy / Q000209:etiology; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D005776:Gaucher Disease / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D005962:Glucosylceramidase / Q000009:adverse effects / Q000627:therapeutic use*; D006454:Hemoglobins / Q000378:metabolism; D006596:Hexosaminidases / Q000097:blood; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011788:Quality of Life; D011994:Recombinant Proteins / Q000627:therapeutic use; D012383:Romania; D012720:Severity of Illness Index; D013156:Splenectomy; D013163:Splenomegaly / Q000188:drug therapy / Q000209:etiology; D013921:Thrombocytopenia / Q000188:drug therapy / Q000209:etiology; D013997:Time Factors; D016896:Treatment Outcome; D015430:Weight Gain / Q000187:drug effects
chemical_list: D006454:Hemoglobins; D011994:Recombinant Proteins; D006596:Hexosaminidases; C086400:chitotriosidase; D005962:Glucosylceramidase; C090568:imiglucerase
references: Hum Genet. 1983;64(3):227-31
references: 6885065
references: Am J Obstet Gynecol. 2004 Feb;190(2):435-41
references: 14981386
references: J Inherit Metab Dis. 2005;28(4):585-92
references: 15902562
references: Bull Acad Natl Med. 2002;186(5):851-61; discussion 861-3
references: 12412377
references: J Clin Invest. 1994 Mar;93(3):1288-92
references: 8132768
references: Blood. 2006 Aug 1;108(3):830-5
references: 16527890
references: J Inherit Metab Dis. 2006 Feb;29(1):92-8
references: 16601874
references: Semin Hematol. 2004 Oct;41(4 Suppl 5):15-22
references: 15468046
references: Intern Med J. 2005 Mar;35(3):156-61
references: 15737135
references: Blood Cells Mol Dis. 1998 Mar;24(1):73-81
references: 9541479
references: Genet Med. 2005 Feb;7(2):105-10
references: 15714077
references: Arch Biochem Biophys. 1976 Aug;175(2):569-82
references: 958319
references: J Biol Chem. 1998 Oct 2;273(40):25680-5
references: 9748235
references: Arch Intern Med. 2000 Oct 9;160(18):2835-43
references: 11025794
references: Orv Hetil. 2003 Apr 20;144(16):749-55
references: 12778625
references: Medicine (Baltimore). 1992 Nov;71(6):337-53
references: 1435229
references: Sangre (Barc). 1997 Jun;42(3):189-94
references: 9381260
references: Eur J Hum Genet. 2002 Sep;10(9):511-5
references: 12173027
references: Am J Med. 2002 Aug 1;113(2):112-9
references: 12133749
references: Clin Chim Acta. 1990 Dec 24;194(2-3):161-6
references: 2093469
references: J Formos Med Assoc. 2002 Sep;101(9):627-31
references: 12645190
references: Blood Cells Mol Dis. 2002 Mar-Apr;28(2):288-96
references: 12064924
references: Lancet. 1990 Jun 30;335(8705):1589-90
references: 1972504
references: Semin Hematol. 2004 Oct;41(4 Suppl 5):4-14
references: 15468045
references: Genet Test. 1997;1(1):5-12
references: 10464619
references: Baillieres Clin Haematol. 1997 Dec;10(4):691-709
references: 9497858
references: Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10544-7
references: 1961718